Zacks Investment Research
06 Jul 2026, 15:45 UTC · 2h ago
Reasons Why Investors Should Consider Betting on Neurocrine Stock
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Jul 2026, 15:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Neurocrine Biosciences' flagship drug Ingrezza generated $656.9 million in Q1 2026 net product sales, a 20% year-over-year increase. — Strong top-line growth and record patient starts for a primary revenue driver typically drive positive valuation adjustments.
+0.60Management reaffirmed full-year 2026 sales guidance for Ingrezza at $2.7 billion to $2.8 billion. — Guidance reaffirmation provides predictability and reduces uncertainty for investors regarding the company's core asset.
+0.40The newly launched drug Crenessity is showing consistent quarter-over-quarter commercial growth and expanding reimbursement coverage. — Successful commercialization of a second product reduces dependency on a single drug and diversifies the revenue stream.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Neurocrine has a late-stage pipeline including direclidine in phase III for schizophrenia and bipolar mania. — Pipeline progression represents future growth potential, though phase III results are binary risks.
+0.20Which stocks this story touches
The article highlights strong commercial performance of marketed drugs, positive sales growth for Ingrezza, and a robust pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
12h ago
